Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated:  1/5/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated: 1/5/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated:  1/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated: 1/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated:  1/5/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated: 1/5/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated:  1/5/2017
Local Institution
mi
from
Creteil Cedex,
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated: 1/5/2017
Local Institution
mi
from
Creteil Cedex,
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated:  1/5/2017
John Theurer Cancer Center
mi
from
Hackensack, NJ
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Enrolling
Updated: 1/5/2017
John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
UCLA
mi
from
Los Angeles, CA
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Dana Faber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
University of Michigan Health System
mi
from
Ann Arbor, MI
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
John Theurer Cancer Center
mi
from
Hackensack, NJ
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Portland Providence Medical Center
mi
from
Portland, OR
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Portland Providence Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
University of Virginia School of Medicine
mi
from
Charlottesville, VA
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
University of Virginia School of Medicine
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated:  1/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Status: Enrolling
Updated: 1/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Testing a Personalize Medication Log for Patients With Lymphoma
Testing a Personalize Medication Log for Patients With Lymphoma
Status: Enrolling
Updated:  1/10/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Testing a Personalize Medication Log for Patients With Lymphoma
Testing a Personalize Medication Log for Patients With Lymphoma
Status: Enrolling
Updated: 1/10/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
Feasibility of Implementing Yoga Intervention for Adolescents at St. Jude Children's Research Hospital
Status: Enrolling
Updated:  1/12/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
Feasibility of Implementing Yoga Intervention for Adolescents at St. Jude Children's Research Hospital
Status: Enrolling
Updated: 1/12/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Mayo Clinic Scottsdale
mi
from
Phoenix, AZ
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Mayo Clinic Scottsdale
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
University of Miami Sylvester Comprehensive Cancer
mi
from
Miami, FL
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
University of Miami Sylvester Comprehensive Cancer
mi
from
Miami, FL
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
University of Michigan Comprehensive Cancer Center Division of Hematology Oncology
mi
from
Ann Arbor, MI
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
University of Michigan Comprehensive Cancer Center Division of Hematology Oncology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Columbia Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Columbia Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Weill-Cornell Medical College
mi
from
New York, NY
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated:  1/25/2017
Universitatsmedizin der Johannes Gutenberg- Universitat
mi
from
Mainz,
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Status: Enrolling
Updated: 1/25/2017
Universitatsmedizin der Johannes Gutenberg- Universitat
mi
from
Mainz,
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Children's Hospital of Alabama at University of Alabama at Birmingham
mi
from
Birmingham, AL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Children's Hospital of Alabama at University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
All Children's Hospital
mi
from
St. Petersburg, FL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
All Children's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Children's Healthcare of Atlanta / Emory University
mi
from
Altanta, GA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Children's Healthcare of Atlanta / Emory University
mi
from
Altanta, GA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Boston Children's Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated:  2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated: 2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials